NIH GUIDE, Volume 24, Number 42, April 18, 2018

Daniel Bednarik 

P.T. 34


  Ethics/Values in Science & Technol; Daniel Bednarik 

  Grants Administration/Policy+

Daniel Bednarik

In anticipation of any future inquiries, I have provided my description as an affidavit of an event that occurred in my career 24 years ago. I have also attached a link to a letter from a colleague who was aware of the actual circumstances surrounding this incident. Please feel free to contact him or me directly if you have any further questions or concerns.

I Daniel Bednarik, affirm that I was part of an ORI investigation while working for the CDC in 1990. The issue was due to an error in one manuscript identified by a journal referee who questioned whether this data was not properly represented. There was no fabrication in the submitted manuscripts — My Division Chief at that time confiscated key laboratory notebooks that contained original raw data demonstrating the work was accurately completed; I and others in this Branch testified that certain pivotal notes and data were withheld and/or not provided to ORI investigators that would have cleared me. Multiple individuals from this laboratory testified to a “alternative agenda”, but ORI was unrelenting and maintained that I could not prove the work was actually done without the additional information. I have never been able to prove or provide the original and highly probative data that was missing.  Being a young and very naive PI,  I exhausted all financial options available to me at that time and I decided to voluntarily exclude myself from applying for Federal grant funding for a period of two years.  Such “voluntary exclusions” are commonplace but are often misconstrued as an implication of guilt – it clearly was not to be construed as an admission of guilt as was defined by the ORI ruling.  This ruling only means that either side could not prove its case resulting in a settlement.  I regret settling with the ORI as the accusation was false and did not rise to the level of misconduct.  The exclusion period has long since expired but remains indexed by Google.

A good read that captures what to do when falsely accused of misconduct can be found here — . My situation is described under Point #3:  

  1. “Machiavellists”

“These persons have a political motivation to ruin the reputation of a scientists for example in the context of elections for important positions such as dean, rector etc. Also in this case it is difficult to evaluate whether the accusations are true or just a political game. Sometimes small justified allegations which would be considered as ‘sloppiness’ or ‘honest error‘ may be exaggerated and followed up by an institution or a commission in a ‘vendetta style’ with destructive effects on the reputation of a scientist. These persons intentionally abuse the whistleblower status.”

Since that incident, I have been productive in obtaining external funds, with my coauthorship of a 2006 DARPA contract proposal as one example, and funding from the Canadian Institutes of Health Research (CIHR) as another. I have also extensively published in peer reviewed journals. My successful employment history at Human Genome Sciences, Gene Logic, Artesian Therapeutics, Cardiome Pharma, Diaxonhit Therapeutics and Intrexon Corp. is validation of my integrity and reflects these companies’ full support of me. I have also succeeded in obtaining venture funding via Oxford Bioscience Partners, the Maryland Dept. of Business & Economic Development, and Brown Advisory, Baltimore that also attests to my professional track record, integrity, and the comfort of the individual investors with my record. The ORI ruling was independently reviewed by the DARPA Project Manager and Defense Dept. General Counsel who further confirmed this not considered to be an issue or concern.

If it is of any help to people who read this rebuttal and if you are a junior investigator early in your career, ALWAYS make sure to make copies of everything; raw data, notebooks, etc. to keep in your possession to protect against those supervisors who are sociopaths and create artificially pressurized environments to advance their own publication goals and heighten their self perceptios.

If you wish to inquire further, please contact Dr. Paul W. Doetsch at Emory University, who was witness to the evolution of this incident, I would encourage you to read the letter below.

Dr. Doetsch’s contact information can be found at his Institutional website  – Contact Information for Dr. Paul Doetsch 

Daniel Bednarik, Ph.D.

Daniel Bednarik’s Profile Page 

Emory University Support Letter


Daniel Bednarik is scientist who works and studies within the field of biopharmaceutical and medical research. Daniel’s experience working in his field includes leading the cultivation and implementation of inventive, adaptive technologies that apply to the conducting of research within the clinical field of study.  He has extensive knowledge within practice of heading the creative process of product development along with the business extension within newly-formed companies, as well as long-established businesses. He holds a deep understanding of genomics database design and application, and is competent in the process behind the development of bioinformatics equipment.

Daniel Bednarik is a trained professional in the niche of infectious diseases and has contributed to the enhancement of the use of animal model studies by working on animal model development in the realm of biopharmaceutical field.  He also has contributed his knowledge and experience to the endeavor of the stratification of clinical trials that utilize human biomarkers.  Daniel Bednarik has served as an active member of the FDA Advisory Committee, and has taken part in the discourse and administration behind their regulatory dealings.  Daniel has authored and submitted numerous IND, IDE, BLA and CMC regulatory documents for review and publication. While he seen a great deal of success within his field, one of his noteworthy career moments in which he feels a great deal of pride is his co-founding role in the creation and launch of Artesian Therapeutics, Inc.  For this business, Daniel is responsible for raising $5M worth of private equity funding for the startup business.  Along with these impressive accomplishments, Daniel has done a great deal of consulting within his field of biopharmaceutics and is frequently sought out for his wisdom and advice. 

Currently, Daniel Bednarik is a Senior Vice President who will be defining the molecular engineering and protein design for a novel approach to immunotherapy that will be paradigm-changing and completely proprietary.  Prior to taking on this new venture, Danial Bednarik worked at Intrexon Corporation, in Germantown, Maryland, where he served as the Vice President of  the Operations of the Molecular Engineering Unit within the company.  In his role, Daniel offered support by way of his understanding of molecular engineering for the various branches of the company, as well as dealt with “External Channel Partner,” collaborations in terms of proprietary gene design technology imperative to the facilitation of drug and/or product cultivation across a wide range of corporate divisions and sectors.  As VP of the MEU, he worked alongside the Chief Scientific Officer (MEU) in a number of situations, along with the company’s President, the Human Therapeutics Division (HTD), and the Cell Engineering Unit (CEU) in order to improve and grow the translation of technology to application in the clinic or other areas.

During his time at Intrexon, Daniel specialized in a number of niches, one of which was the leading of the molecular measures for the Corporations.  The other areas he worked within included the management of 14 direct reports, developing, cultivating and running testing for orally activated gene therapy solutions. Daniel Bednarik has come up with novel methodologies for coming to solid conclusions regarding gene therapy issues and can claim responsibility for the development of new ideas for platforms for production of new important discoveries that are derived from cell-based research.  He is knowledgable of and has experience in biopharmaceutical efforts and studies dealing with veterinary work, food science, health sectors and bioinformatics, to name a few.

Prior to his role at Intrexon, Daniel Bednarik filled the role of Director of the Scientific Advisory Board at Albitech in Baltimore, Maryland.  Earlier than that, he was the co-founder and vice-president of Artesian Therapeutics, a company that was ultimately acquired by Cardiome Pharma in 2005.  After this acquisition, Daniel joined the Cardio Pharma team.  Daniel’s vast and deep experience along with his varied background in biopharmaceuticals enable him to be a highly successful, reputable figure in his area of expertise.

Other Examples..

“Who steals my purse steals trash,” Shakespeare wrote, but one who “filches [another’s] good name” takes “the immediate jewel of their souls.” The play is Othello, but he could just as well have been writing about science, where reputation is, in the words of the University of Washington’s (UW’s) policy on research misconduct, “of paramount importance to a researcher’s career.” So when UW dismissed longtime staff researcher Mercedes Perez-Melgosa after her lab chief, genome sciences professor Deborah “Debbie” Nickerson, concluded that Perez-Melgosa had “changed data,” as Nickerson would testify in a May 2015 court trial, Perez-Melgosa was devastated. It felt as if “my scientific career, my professional career—a very big part of my life had disappeared in front of me,” Perez-Melgosa testified in the same Seattle courtroom as part of a lawsuit she brought against UW related to her termination. 

Perez-Melgosa believes she has been unjustly accused of falsification, which is an element of career-killing scientific misconduct. She denies changing data and wanted a panel of competent and impartial scientific experts to examine the evidence, but the relevant UW unit, then known as the Office of Scholarly Integrity (OSI) and now called the Office of Research Misconduct Proceedings, did not investigate the case. As this never happened, the question of whether she changed or only interpreted data appears to remain unsettled. To read more, visit –>

New CDC chief stepped down from four groups to comply with ethics rules

CDC Director Robert Redfield, a longtime AIDS researcher, took over as CDC chief on March 26, 2018. (CDC)

Centers for Disease Control and Prevention Director Robert Redfield has resigned his  positions at four groups, including a gene therapy biotechnology company and a conservative AIDS organization, to comply with government ethics rules, according to his financial disclosures.

Redfield, a longtime HIV/AIDS researcher who started the job March 26, succeeded Brenda Fitzgerald, the former Georgia public health commissioner, who resigned Jan. 31 after serving only half a year because she was unable to divest from her financial holdings. She had also purchased tobacco stocks as CDC director.

“The job of CDC Director is very important to me,” Redfield said in a statement issued Tuesday. “Therefore, I have worked closely with the HHS Ethics Office to comply with all reporting requirements of the Ethics in Government Act.”

To Your Health newsletter

Health news and research, in your inbox weekly.

Sign up

His public financial disclosure report has been reviewed by the ethics office of the Health and Human Services Department, to which the CDC belongs.

Redfield, a professor of medicine at the University of Maryland, said he has also divested stock holdings in two private biotechnology companies and is recusing himself from participating in matters involving the university and seven organizations, according to his ethics agreement and a memorandum about his recusals provided to The Washington Post by an individual with knowledge of the plans.


Among the organizations from which Redfield has resigned his positions:

* American Gene Technologies International Inc., a Rockville, Md., gene therapy company where Redfield served since 2011 as an adviser and later chair of the clinical advisory board for its HIV cure program. Redfield earned consulting fees of $57,250 from the beginning of 2017 through March 2018.

* Children’s AIDS Fund International, a faith-based AIDS organization, where Redfield has served as a director since 2003.

* Guidepoint Global, LLC, where Redfield had been a consultant since 2014. He earned $1,508 from the beginning of 2017 through March 2018.

Redfield sold his stock in Profectus BioSciences, a Baltimore vaccine-development company, before he started the CDC job, and in American Gene Technologies, according to his ethics agreement.

Redfield also will no longer work as a consultant for four law firms or as a speaker for a medical education company. He said he plans to sign over his share of royalties from a forthcoming book about HIV infections to his co-author and future licensing fees or royalties on several patents to the University of Maryland.

His compensation from the university from the beginning of 2017 through March 2018 was $757,100 plus a $70,000 bonus, according to his public financial disclosure.

Read more:

In emotional speech, CDC’s new director vows to uphold science

CDC Director Brenda Fitzgerald faces questions about financial conflicts of interest

CDC gets list of words to avoid: fetus, transgender, diversity

 Banned from AdSense?

ping fast  my blog, website, or RSS feed for Free

Daniel Bednarik, Ph.D.

Daniel Bednarik, Ph.D.

13055 St. Patrick’s Ct. – Highland, MD 20777 – (443) 864.1445 –

Profile:  Executive * Translational Scientist * Consultant

Accomplished and tenacious biopharmaceutical researcher and manager with extensive experience in leading the development of new clinical and research technologies and in guiding business and product development by new and established companies.

  • Genomics and bioinformatics database design/implementation – Cardiovascular emphasis
  • Expert in viral infectious diseases – Emphasis on retrovirology, herpes virology
  • Animal model development – Cardiovascular and infectious disease relevance
  • Translational medicine – Genomic-based discoveries to small molecule therapeutics
  • Stratification of cardiovascular clinical trials using human biomarkers
  • FDA Advisory Committee participation in Cardiome Pharma cardiovascular trials
  • Co-Founder of Artesian Therapeutics, Inc. – Heart failure drug discovery
  • Extensive consulting experience across multiple genomic, infectious disease, and cardiovascular applications
  • Experienced with Dept. of Defense funding processes – DARPA/BARDA

Professional Cardiovascular Experience (Chronologically Descending Order)

Cardiome Pharma Corporation – 2005 to 2012

Cardiome Pharma is a research & development-based biopharmaceutical company dedicated to the discovery, development, and commercialization of new therapies focusing on the treatment of atrial fibrillation and heart failure with one product, Brinavess™ (vernakalant IV) approved in Europe and partnered with Merck.

Director of Cardiovascular Genomics & Bioinformatics, 2007–2012

Identified, recommended, and facilitated the integration of current and new bioinformatics and genomic technologies to assist in development and preclinical and clinical testing of the company’s pharmaceutical product pipeline. Designed biomarker strategies and complimentary animal models for early preclinical studies and worked with project teams to advance biomarker, genetic, and translational medicine study plans. Advanced project milestones with the goal of identifying individuals who do not respond to particular drugs.

  • Lead manager for the company’s acquired Beta-Receptor Pathway Modulator (BRPM) heart failure program.
  • Identified targets and designed studies for new ion channel antagonist small molecules.
  • Developed arrhythmia biomarker FDA genetic sub-study for Vernakalant Oral Phase-IIb clinical trial and database development.
  • Developed Cardiac Hypertrophy Inhibitory Pathway Modulator (CHIPM) program targeting CXCR4 receptor to inhibit cardiac hypertrophy and remodeling.
  • Introduced new bioinformatics approaches to stratify cardiovascular clinical trials.
  • Identify potential biomarkers and efficacy surrogates for use in clinical trials and advise regarding the evolution of FDA and EMEA guidelines for the use of biomarkers.
  • Designed animal models for pre-clinical studies.
  • Participated with Merck on partnering/FDA meetings for Vernakalant program.

Consultant (post acquisition), Scientific Affairs & Cardiovascular Disease, 2005–2007

Managed the post-acquisition drug program transition and integration of Artesian Therapeutics assets, and supported the design, molecular screening, and animal model testing of Artesian compound libraries.

  • Managed acquired Beta-Receptor Pathway Modulator (BRPM) and Calcium Regulatory Pathway Modulator CRPM programs (Artesian).
  • Prepared program proposals for a new theranostic drug-development paradigm.

Artesian Therapeutics, Inc. – 2002 to 2005

Vice President & Co-Founder, Cardiovascular Biology, Artesian Therapeutics, Inc., 2002–2005

Artesian Therapeutics was a discovery-based biotechnology company that translated the gene expression technology and transcriptome content from gene logic into therapeutic drug leads. Artesian was a spinout from Gene Logic Inc. a company based on using of new gene-expression technology to determine gene-expression patterns in diseased tissue and cells.

  • Co-Founder of Artesian Therapeutics, Inc. via Oxford BioScience Partners (Cambridge, MA).
  • Identified pivotal heart disease genes and translated findings to 3 led drug candidates for the treatment of heart failure.
  • Established an in vitro analysis paradigm for drugs and validation paths for CRPM and BRPM Program small-molecule development for IND filing.
  • Designed data-driven, animal model studies for heart failure and cardiovascular disease.
  • Developed the proprietary Affimetrix GeneChip® database for heart failure drug discovery and patented more than 275 heart failure gene-expression profiles for diagnostics and therapeutics.
  • Raised $7M in venture capital (Oxford Bioscience Partners) and was instrumental in executing the VC partners’ exit strategy of finding a buyer (Cardiome) for Artesian.

Gene Logic, Inc. – Gaithersburg, MD

Scientific Director, Cardiovascular Database Product Development 1997–2002

Gene Logic was a discovery-based biotechnology company that pioneered gene-expression based content comparing transcriptomic profiles from diseased tissue and cells to healthy, normal equivalents. The company licensed this content to major pharmaceutical firms for drug target discovery, with focus in multiple disease categories including cardiovascular, cancer, and cns.

  • Designed and deployed the largest known database for heart failure and vascular disease in collaboration with Proctor & Gamble, Temple University Medical School, and Tufts University.
  • Designed preclinical animal model studies for heart failure and cardiovascular disease to elucidate disease gene-expression profiles.
  • Translated gene-expression data into marketable information for subscription by multiple world-class pharmaceutical companies.
  • Defined and secured collaborative human tissue-procurement and research alliances with major heart failure centers, hospitals, and universities worldwide.
  • Participated in the development of GeneChip®-based paradigms and algorithms for data mining, drug discovery, development, and regulatory process.
  • Provided business- and product-development strategies to management and established relationships with 7 major pharmaceutical industry subscribers focused in cardiovascular disease.
  • Cardiovascular Experience (Chronologically Ascending Order)
  • Cardiovascular Experience (Chronologically Ascending Order)

Non-Cardiovascular Experience (Descending Chronology)

Intrexon Corporation – Germantown, MD, 2012 (present)

Senior Director Operations, Molecular Engineering Unit Operations (MEU) 2012

Intrexon Corporation is a billion dollar capitalized company that designs novel gene therapy solutions. Intrexon’s approach is to combine the principles of precision engineering, statistical modeling, automation, and production at an industrial scale for the development of improved or novel products.

  • Provides molecular engineering support for the company’s programs and pharma partnering in terms of proprietary gene design technology needs to facilitate drug and/or product development across a spectrum of corporate divisions and sectors.
  • Health sector disease areas include cardiovascular, inflammation, cancer, infectious disease, and veterinary applications.
  • Works closely with the Chief Scientific Officer, President, Human Therapeutics Division (HTD), and the Cell Engineering Unit (CEU) to accelerate translation of gene therapy technology to applications in the clinic.

Ablitech – Baltimore, MD 2012

A startup firm with a proprietary technology for delivering nucleic acid-based drugs, the firm has received approximately $2M in funding through a Department of Defense contract.

Director, Scientific Advisory Board

Assembled and presently lead an advisory board of recognized scientific experts to guide corporate goals and ensure scientific integrity. The board oversees multiple grant-funding initiatives and maximizes capitalization for forward-looking fiscal objectives and assists the CEO in identifying and enabling private equity investors. It also manages all translational application of the core technology and identifies appropriate corporate and academic partnerships.

Cardiome Pharma Corporation – 2005 to 2012

Head, Infectious Disease Pilot Program, 2011–2012

As described above – Ion channel infectious disease therapeutics program

Conceived and developed a novel viral ion channel target program using synthetic biology approaches for the screening and testing of new, best-in-class antiviral molecules.

  • Develop and implement a screening platform to identify novel inhibitors of the viroporins for several problem viruses.
  • Determine the effectiveness of identified molecules to block the life cycles of HCV, Dengue, and Influenza viruses.
  • Implement strategy for validation, IND filing, and progression into the clinic.
  • Seek and execute new pharma partners for development of ion channel-based antivirals.

Advanced Bioresearch Associates, Rockville, MD 1997

A regulatory consulting firm serving the pharmaceutical and medical device industries.

Director of Scientific Affairs

Performed due diligence of scientific and technical literature and prepared reports for IND submissions to the FDA and for corporate and venture partners of startup companies in these spaces. Served as a primary consultant for new product development to pharmaceutical and medical device companies.

Human Genome Sciences, Inc. – Rockville, MD 1993–1997

A biopharmaceutical corporation founded in 1992, it utilizes the human genome to develop protein and antibody drugs and, in partnership with such firms as GlaxoSmithKline, have drugs under development to treat such diseases as hepatitis C, systemic lupus erythmatosis, anthrax, and cancer.

Senior Scientist

Identified, sequenced, and cloned novel human genes for the development of therapeutic proteins. Performed bioinformatics analysis on novel human genes, and prioritized gene selection for therapeutic development. Led the acquisition of all human tissues and sequencing of genes from those tissues. Supervised two technicians and was a key contributor to the development of one of the world’s largest bioinformatics databases.

  • Co-authored patents for 182 secreted proteins as therapeutic development candidates.
  • Identified and cloned novel seven-transmembrane receptors for development by GlaxoSmithKline (GSK).
  • Developed high-throughput biological validation assays for functional analysis of human genes, and pre-clinical animal models.

Consulting Experience

  • Immune Design Corp., Seattle, WA, 2011
  • CD Diagnostics, Inc., Philadelphia, PA, 2010-2011
  • Indel Therapeutics, Inc., Vancouver, BC, 2009-Present
  • ProteiosBio LLC, Charlottesville, VA, 2011
  • NX PharmaGen, Inc., Miami, FL, 2009-Present
  • BioIT Solutions, Inc., Silver Spring, MD, 2012-Present
  • Susavion Biosciences, Inc., Tempe, AZ, 2012
  • Cardioxyl Pharmaceuticals, Inc., Towson, MD, 2007-2009
  • ExonHit Therapeutics, Inc., Gaithersburg, MD, 2007-2009 (Consulting Director, Business Development)
  • Bradmer Pharmaceuticals, Inc., Miami, FL 2006-2009
  • Advanced Bionutrition (ABN), Columbia, MD, 2006


The Johns Hopkins Oncology Center, The Johns Hopkins University         1985–1989

Postdoctoral Fellow / Junior Faculty Member (Instructor)

Studied mechanisms of viral latency, and molecular mechanisms of interferon action. Participated in department programmatic development and teaching and authored multiple publications and book chapters.

  • Discovered DNA methylation as a mechanism for HIV latency and mechanisms of HIV activation by herpes simplex and cytomegalovirus.
  • Elucidated novel biological pathways for interferon-mediated inhibition of HIV transcription and assembly.
  • Developed novel recombinant gene therapy modalities for the inhibition of HIV transcription.

Temple University School of Medicine                                                 Ph.D. in Biochemistry, 1985

M.S. in Biochemistry, 1982

Rider University                                                                                          B.A. in Biology, 1980

Grants & Contracts

  • Canadian Institutes of Health Research (CIHR). A Novel Approach for the Discovery & Development of New Antiviral Therapeutics (Awarded); Partnered Operations Grant Application – Cardiome Pharma Corp. & University of British Columbia (2012). Total $1,900,000 for 5 years.
  • American Foundation for AIDS Research (AmFAR). Methylation as a Modulator of Expression of HIV.  Research Grant #RG-000639 (1989-1991); Total direct costs $50,000; Total indirect costs $9,100.
  • The National Institutes of Health (NIH). Regulation of HIV Latency by Methylation of Proviral DNA.  Young Investigator Award; #1-R29-AI-28567-01A1-ARR3 (1989).  Total direct costs $350,000; Total indirect costs $224,686.
  • DARPA BAA 06-31. “Crustacean Expression System for the Accelerated Manufacture of Pharmaceuticals.” 42 month term – $6.2M  (2006) – Phase-I awarded (DTRA contract HDTRA1-07-C-0078 $1.7M Phase-I, Advanced BioNutrition Corp. (Consultant for ABN).
  • Upon Request

Publications, Patents, & Additional Background

Selected Publications

Margulies KB, Bednarik DP, Dries DL. Genomics, transcriptional profiling, and

heart failure. J Am Coll Cardiol. 2009 May 12;53(19):1752-9. doi:

10.1016/j.jacc.2008.12.064. Review. PubMed PMID: 19422981; PubMed Central PMCID:


Margulies KB, Matiwala S, Cornejo C, Olsen H, Craven WA, Bednarik D. Mixed

messages: transcription patterns in failing and recovering human myocardium. Circ

Res. 2005 Mar 18;96(5):592-9. Epub 2005 Feb 17. PubMed PMID: 15718504.

Jung AS, Quaile MP, Mills GD, Bednarik DP, Houser SR, Margulies KB.

Pharmacological effects of ATI22-107



lic acid dimethyl ester)], a novel dual pharmacophore, on myocyte calcium cycling

and contractility. J Pharmacol Exp Ther. 2005 Feb;312(2):517-24. Epub 2004 Nov

18. PubMed PMID: 15550574.

Please see Dan Bednarik Profile

Daniel Bednarik

Daniel Bednarik’s Background

BIOSKETCH: Daniel Bednarik was previously Director of Genomics and Bioinformatics for Cardiome Pharma Corporation. He was previously co-founder and Vice President of Cardiovascular Biology of Artesian Therapeutics, Inc., which was acquired by Cardiome in 2005. Dr. Bednarik served as a consultant for Cardiome for two years and was subsequently hired in 2007 to develop genomic and proteomic biomarker programs to help augment and accelerate clinical trial design. He created the largest known cardiovascular gene expression database for Gene Logic. Dr. Bednarik served as a key scientist for the development of Human Genome Sciences’ (HGS) database and has over 28 years experience in the field of virology with emphasis on HIV and herpes virus pathology. He was co-recipient of a DARPA contract in 2006 where he and his colleagues developed a novel non-host method for rapid vaccine manufacture. Dan also is experienced in developing and managing clinical programs. His training was completed at Temple University School of Medicine (Philadelphia) in 1985, and The Johns Hopkins University Oncology Center (Baltimore).

IN MY CURRENT POSITION OF SENIOR DIRECTOR, MOLECULAR ENGINEERING UNIT (MEU) OPERATIONS, I provide molecular engineering support for the company’s programs and “External Channel Partner” collaborations in terms of proprietary gene design technology needs to facilitate drug and/or product development across a spectrum of corporate divisions and sectors.  Works closely with the Chief Scientific Officer (MEU), President, Human Therapeutics Division (HTD), and the Cell Engineering Unit (CEU) to accelerate translation of technology to application in the clinic or other venues.

Key areas include:

  1. Construction of orally inducible gene therapy solutions – biologic, RNAi.
  2. Novel delivery of gene therapy solutions – viral, nonviral, nanoparticle.
  3. Novel cell-based production platform development.
  4. Veterinary, food science, health sector, bioinformatics, and other.

Specialties:Recruitment of private capital, Bioinformatics/Genomics, Clinical Program Development & Management, Pharmacogenomics, Virology, Translational Medicine, Heart Disease.

Please visit my LinkedIn Profile –